IFNA2 (interferon alpha 2) encodes the prototypic human type I interferon that serves as a critical antiviral cytokine with broad immunomodulatory functions 1. As the first highly active IFN subtype to be cloned and commercialized, IFNA2 has been instrumental in elucidating type I interferon mechanisms of action 1. The protein exhibits potent antiviral activity against various viral infections, including HIV, where different IFNα subtypes show varying therapeutic efficacy 2. IFNA2 demonstrates specialized roles in immune responses, with distinct transcriptional signatures associated with antiviral responses in circulating immune cells during COVID-19 infection 3. The gene shows differential expression patterns in various disease contexts, including reduced expression in diabetic retinopathy where it is negatively regulated by miR-499-3p, leading to enhanced TLR4 signaling pathway activation 4. Genetic polymorphisms in IFNA2, particularly the -173 variant combined with IFNA8 -884A haplotype, are associated with reduced IFN-α production, increased susceptibility to severe malarial anemia, and higher all-cause mortality in pediatric populations 5. Additionally, IFNA2 expression alterations have been identified in basal cell carcinoma, suggesting potential roles in autophagy regulation and cancer progression 6.